nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—Cytarabine—Gemcitabine—urinary bladder cancer	0.254	0.35	CrCrCtD
Vidarabine—Azacitidine—Gemcitabine—urinary bladder cancer	0.242	0.333	CrCrCtD
Vidarabine—Decitabine—Gemcitabine—urinary bladder cancer	0.23	0.317	CrCrCtD
Vidarabine—DPP4—Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)—CDX2—urinary bladder cancer	0.00717	0.0869	CbGpPWpGaD
Vidarabine—DPP4—Incretin synthesis, secretion, and inactivation—CDX2—urinary bladder cancer	0.00638	0.0773	CbGpPWpGaD
Vidarabine—ADA—prostate gland—urinary bladder cancer	0.00519	0.0829	CbGeAlD
Vidarabine—ADK—prostate gland—urinary bladder cancer	0.00424	0.0678	CbGeAlD
Vidarabine—DPP4—prostate gland—urinary bladder cancer	0.00411	0.0657	CbGeAlD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—KRT5—urinary bladder cancer	0.00382	0.0463	CbGpPWpGaD
Vidarabine—ADK—seminal vesicle—urinary bladder cancer	0.00359	0.0573	CbGeAlD
Vidarabine—ADA—renal system—urinary bladder cancer	0.00354	0.0565	CbGeAlD
Vidarabine—DPP4—seminal vesicle—urinary bladder cancer	0.00348	0.0556	CbGeAlD
Vidarabine—DPP4—epithelium—urinary bladder cancer	0.00302	0.0483	CbGeAlD
Vidarabine—ADK—smooth muscle tissue—urinary bladder cancer	0.003	0.048	CbGeAlD
Vidarabine—DPP4—smooth muscle tissue—urinary bladder cancer	0.00291	0.0465	CbGeAlD
Vidarabine—ADK—renal system—urinary bladder cancer	0.00289	0.0462	CbGeAlD
Vidarabine—Cytarabine—POLB—urinary bladder cancer	0.00284	0.362	CrCbGaD
Vidarabine—ADK—urethra—urinary bladder cancer	0.00284	0.0454	CbGeAlD
Vidarabine—ADA—female reproductive system—urinary bladder cancer	0.00283	0.0453	CbGeAlD
Vidarabine—DPP4—renal system—urinary bladder cancer	0.0028	0.0448	CbGeAlD
Vidarabine—ADA—C-MYB transcription factor network—PTCRA—urinary bladder cancer	0.00263	0.0318	CbGpPWpGaD
Vidarabine—ADORA2A—female reproductive system—urinary bladder cancer	0.00258	0.0412	CbGeAlD
Vidarabine—ADA—vagina—urinary bladder cancer	0.00256	0.0409	CbGeAlD
Vidarabine—ADK—Nucleotide metabolism—TYMP—urinary bladder cancer	0.00248	0.0301	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—TP63—urinary bladder cancer	0.00232	0.0281	CbGpPWpGaD
Vidarabine—ADK—female reproductive system—urinary bladder cancer	0.00232	0.037	CbGeAlD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—VHL—urinary bladder cancer	0.00225	0.0273	CbGpPWpGaD
Vidarabine—DPP4—female reproductive system—urinary bladder cancer	0.00225	0.0359	CbGeAlD
Vidarabine—DPP4—Peptide hormone metabolism—CDX2—urinary bladder cancer	0.00216	0.0262	CbGpPWpGaD
Vidarabine—ADK—Purine metabolism—GPX1—urinary bladder cancer	0.00211	0.0256	CbGpPWpGaD
Vidarabine—ADK—vagina—urinary bladder cancer	0.00209	0.0334	CbGeAlD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—TP63—urinary bladder cancer	0.00207	0.0251	CbGpPWpGaD
Vidarabine—DPP4—vagina—urinary bladder cancer	0.00203	0.0324	CbGeAlD
Vidarabine—ADK—Nucleotide metabolism—RRM2—urinary bladder cancer	0.00194	0.0235	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—IGFBP3—urinary bladder cancer	0.00182	0.022	CbGpPWpGaD
Vidarabine—Clofarabine—RRM2—urinary bladder cancer	0.00181	0.231	CrCbGaD
Vidarabine—ADA—Nucleotide metabolism—TYMP—urinary bladder cancer	0.00169	0.0205	CbGpPWpGaD
Vidarabine—ADA—lymph node—urinary bladder cancer	0.00166	0.0265	CbGeAlD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—IGFBP3—urinary bladder cancer	0.00163	0.0197	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—TP63—urinary bladder cancer	0.00153	0.0185	CbGpPWpGaD
Vidarabine—ADA—Purine metabolism—GPX1—urinary bladder cancer	0.00144	0.0174	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—JAG1—urinary bladder cancer	0.00139	0.0168	CbGpPWpGaD
Vidarabine—ADK—lymph node—urinary bladder cancer	0.00135	0.0216	CbGeAlD
Vidarabine—ADA—C-MYB transcription factor network—BIRC3—urinary bladder cancer	0.00133	0.0161	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—NQO1—urinary bladder cancer	0.00132	0.016	CbGpPWpGaD
Vidarabine—ADA—Nucleotide metabolism—RRM2—urinary bladder cancer	0.00132	0.016	CbGpPWpGaD
Vidarabine—DPP4—lymph node—urinary bladder cancer	0.00131	0.021	CbGeAlD
Vidarabine—ADA—C-MYB transcription factor network—MPO—urinary bladder cancer	0.00114	0.0138	CbGpPWpGaD
Vidarabine—ADK—Nucleotide metabolism—TYMS—urinary bladder cancer	0.00112	0.0136	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—KMT2A—urinary bladder cancer	0.00111	0.0135	CbGpPWpGaD
Vidarabine—ADK—Nucleotide metabolism—GPX1—urinary bladder cancer	0.00106	0.0129	CbGpPWpGaD
Vidarabine—Cladribine—RRM2—urinary bladder cancer	0.00104	0.133	CrCbGaD
Vidarabine—Glucosamine—MMP9—urinary bladder cancer	0.000939	0.12	CrCbGaD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—FAS—urinary bladder cancer	0.000908	0.011	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—ATM—urinary bladder cancer	0.000896	0.0109	CbGpPWpGaD
Vidarabine—ADA—Nucleotide metabolism—TYMS—urinary bladder cancer	0.000763	0.00925	CbGpPWpGaD
Vidarabine—ADA—Nucleotide metabolism—GPX1—urinary bladder cancer	0.000722	0.00875	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—NCOR1—urinary bladder cancer	0.000711	0.00861	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—GSTM1—urinary bladder cancer	0.000711	0.00861	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—urinary bladder cancer	0.000682	0.00826	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—FAS—urinary bladder cancer	0.000669	0.00811	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—KMT2A—urinary bladder cancer	0.000638	0.00773	CbGpPWpGaD
Vidarabine—Glucosamine—TNF—urinary bladder cancer	0.000617	0.0786	CrCbGaD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—CDKN2A—urinary bladder cancer	0.00061	0.0074	CbGpPWpGaD
Vidarabine—Adenosine monophosphate—SRC—urinary bladder cancer	0.000596	0.0759	CrCbGaD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—CREBBP—urinary bladder cancer	0.00058	0.00702	CbGpPWpGaD
Vidarabine—DPP4—Peptide hormone metabolism—IGF1—urinary bladder cancer	0.000574	0.00696	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—RB1—urinary bladder cancer	0.000512	0.00621	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—CDKN1A—urinary bladder cancer	0.000499	0.00604	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—CREBBP—urinary bladder cancer	0.000489	0.00593	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—EP300—urinary bladder cancer	0.000475	0.00575	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—CDKN2A—urinary bladder cancer	0.000429	0.00519	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—CDX2—urinary bladder cancer	0.000408	0.00495	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—PTGS2—urinary bladder cancer	0.000401	0.00486	CbGpPWpGaD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—EP300—urinary bladder cancer	0.000395	0.00478	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GSTZ1—urinary bladder cancer	0.000393	0.00476	CbGpPWpGaD
Vidarabine—ADK—Metabolism—NAT1—urinary bladder cancer	0.000373	0.00451	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GSTO2—urinary bladder cancer	0.000373	0.00451	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—CDKN1A—urinary bladder cancer	0.000368	0.00446	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—CCND1—urinary bladder cancer	0.000362	0.00439	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—TYMS—urinary bladder cancer	0.000358	0.00434	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—NCOR1—urinary bladder cancer	0.000354	0.00429	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	0.00035	0.00424	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—EP300—urinary bladder cancer	0.00035	0.00424	CbGpPWpGaD
Vidarabine—Myocardial infarction—Etoposide—urinary bladder cancer	0.000344	0.00286	CcSEcCtD
Vidarabine—Cardiac disorder—Gemcitabine—urinary bladder cancer	0.000342	0.00284	CcSEcCtD
Vidarabine—ADK—Metabolism—UGT2B7—urinary bladder cancer	0.000341	0.00413	CbGpPWpGaD
Vidarabine—ADORA2A—Monoamine Transport—TNF—urinary bladder cancer	0.000336	0.00407	CbGpPWpGaD
Vidarabine—Atrioventricular block—Doxorubicin—urinary bladder cancer	0.000336	0.00278	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—EP300—urinary bladder cancer	0.000333	0.00404	CbGpPWpGaD
Vidarabine—Cough—Thiotepa—urinary bladder cancer	0.000333	0.00277	CcSEcCtD
Vidarabine—Mediastinal disorder—Gemcitabine—urinary bladder cancer	0.000333	0.00276	CcSEcCtD
Vidarabine—Convulsion—Thiotepa—urinary bladder cancer	0.000331	0.00275	CcSEcCtD
Vidarabine—Hypertension—Thiotepa—urinary bladder cancer	0.00033	0.00274	CcSEcCtD
Vidarabine—Arrhythmia—Gemcitabine—urinary bladder cancer	0.00033	0.00274	CcSEcCtD
Vidarabine—Ventricular tachycardia—Doxorubicin—urinary bladder cancer	0.000325	0.0027	CcSEcCtD
Vidarabine—Arrhythmia—Fluorouracil—urinary bladder cancer	0.000324	0.00269	CcSEcCtD
Vidarabine—Anxiety—Thiotepa—urinary bladder cancer	0.000324	0.00269	CcSEcCtD
Vidarabine—Injection site reaction—Doxorubicin—urinary bladder cancer	0.000324	0.00269	CcSEcCtD
Vidarabine—Tinnitus—Cisplatin—urinary bladder cancer	0.000321	0.00266	CcSEcCtD
Vidarabine—Cardiac disorder—Cisplatin—urinary bladder cancer	0.000319	0.00265	CcSEcCtD
Vidarabine—Flushing—Cisplatin—urinary bladder cancer	0.000319	0.00265	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—FAS—urinary bladder cancer	0.000317	0.00384	CbGpPWpGaD
Vidarabine—Hypoaesthesia—Etoposide—urinary bladder cancer	0.000314	0.0026	CcSEcCtD
Vidarabine—Back pain—Gemcitabine—urinary bladder cancer	0.000311	0.00258	CcSEcCtD
Vidarabine—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.00031	0.00257	CcSEcCtD
Vidarabine—Arrhythmia—Cisplatin—urinary bladder cancer	0.000307	0.00255	CcSEcCtD
Vidarabine—ADK—Metabolism—CYP4B1—urinary bladder cancer	0.000307	0.00372	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—MYC—urinary bladder cancer	0.000305	0.0037	CbGpPWpGaD
Vidarabine—Tachycardia—Thiotepa—urinary bladder cancer	0.000304	0.00252	CcSEcCtD
Vidarabine—Vision blurred—Fluorouracil—urinary bladder cancer	0.000298	0.00247	CcSEcCtD
Vidarabine—Cardiac disorder—Etoposide—urinary bladder cancer	0.000292	0.00243	CcSEcCtD
Vidarabine—Flushing—Etoposide—urinary bladder cancer	0.000292	0.00243	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—MYC—urinary bladder cancer	0.00029	0.00352	CbGpPWpGaD
Vidarabine—ADK—Metabolism—SLC19A1—urinary bladder cancer	0.00029	0.00351	CbGpPWpGaD
Vidarabine—Mediastinal disorder—Etoposide—urinary bladder cancer	0.000284	0.00236	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000284	0.00236	CcSEcCtD
Vidarabine—ADK—Metabolism—PRSS3—urinary bladder cancer	0.000282	0.00342	CbGpPWpGaD
Vidarabine—Vision blurred—Cisplatin—urinary bladder cancer	0.000282	0.00234	CcSEcCtD
Vidarabine—Tremor—Cisplatin—urinary bladder cancer	0.000281	0.00233	CcSEcCtD
Vidarabine—Cough—Gemcitabine—urinary bladder cancer	0.00028	0.00233	CcSEcCtD
Vidarabine—Paraesthesia—Thiotepa—urinary bladder cancer	0.00028	0.00232	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—CDK4—urinary bladder cancer	0.000279	0.00338	CbGpPWpGaD
Vidarabine—Cerebrovascular accident—Methotrexate—urinary bladder cancer	0.000278	0.00231	CcSEcCtD
Vidarabine—Hypertension—Gemcitabine—urinary bladder cancer	0.000277	0.0023	CcSEcCtD
Vidarabine—Somnolence—Thiotepa—urinary bladder cancer	0.000277	0.0023	CcSEcCtD
Vidarabine—Convulsion—Fluorouracil—urinary bladder cancer	0.000274	0.00227	CcSEcCtD
Vidarabine—Chest pain—Gemcitabine—urinary bladder cancer	0.000273	0.00227	CcSEcCtD
Vidarabine—Discomfort—Gemcitabine—urinary bladder cancer	0.00027	0.00224	CcSEcCtD
Vidarabine—Chest pain—Fluorouracil—urinary bladder cancer	0.000269	0.00223	CcSEcCtD
Vidarabine—Dysgeusia—Etoposide—urinary bladder cancer	0.000269	0.00223	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—KRAS—urinary bladder cancer	0.000268	0.00325	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTZ1—urinary bladder cancer	0.000267	0.00324	CbGpPWpGaD
Vidarabine—Pain—Thiotepa—urinary bladder cancer	0.000267	0.00221	CcSEcCtD
Vidarabine—Discomfort—Fluorouracil—urinary bladder cancer	0.000266	0.00221	CcSEcCtD
Vidarabine—Back pain—Etoposide—urinary bladder cancer	0.000265	0.0022	CcSEcCtD
Vidarabine—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000262	0.00218	CcSEcCtD
Vidarabine—Cardiac failure—Epirubicin—urinary bladder cancer	0.000262	0.00217	CcSEcCtD
Vidarabine—Cerebrovascular accident—Epirubicin—urinary bladder cancer	0.000261	0.00216	CcSEcCtD
Vidarabine—Convulsion—Cisplatin—urinary bladder cancer	0.000259	0.00215	CcSEcCtD
Vidarabine—Mood swings—Methotrexate—urinary bladder cancer	0.000258	0.00215	CcSEcCtD
Vidarabine—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000258	0.00214	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—IGFBP3—urinary bladder cancer	0.000256	0.00311	CbGpPWpGaD
Vidarabine—Anxiety—Cisplatin—urinary bladder cancer	0.000254	0.00211	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—PPARG—urinary bladder cancer	0.000254	0.00307	CbGpPWpGaD
Vidarabine—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000253	0.0021	CcSEcCtD
Vidarabine—ADA—Metabolism—NAT1—urinary bladder cancer	0.000253	0.00307	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTO2—urinary bladder cancer	0.000253	0.00307	CbGpPWpGaD
Vidarabine—Discomfort—Cisplatin—urinary bladder cancer	0.000252	0.00209	CcSEcCtD
Vidarabine—Tachycardia—Fluorouracil—urinary bladder cancer	0.000252	0.00209	CcSEcCtD
Vidarabine—Affect lability—Epirubicin—urinary bladder cancer	0.000251	0.00209	CcSEcCtD
Vidarabine—Urticaria—Thiotepa—urinary bladder cancer	0.000248	0.00206	CcSEcCtD
Vidarabine—Hypotension—Gemcitabine—urinary bladder cancer	0.000245	0.00203	CcSEcCtD
Vidarabine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000244	0.00203	CcSEcCtD
Vidarabine—Cardiac arrest—Epirubicin—urinary bladder cancer	0.000243	0.00202	CcSEcCtD
Vidarabine—Cardiac failure—Doxorubicin—urinary bladder cancer	0.000242	0.00201	CcSEcCtD
Vidarabine—Mood swings—Epirubicin—urinary bladder cancer	0.000242	0.00201	CcSEcCtD
Vidarabine—Loss of consciousness—Etoposide—urinary bladder cancer	0.000241	0.002	CcSEcCtD
Vidarabine—Cerebrovascular accident—Doxorubicin—urinary bladder cancer	0.000241	0.002	CcSEcCtD
Vidarabine—Hypotension—Fluorouracil—urinary bladder cancer	0.000241	0.002	CcSEcCtD
Vidarabine—Cough—Etoposide—urinary bladder cancer	0.000239	0.00199	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000239	0.00198	CcSEcCtD
Vidarabine—Tachycardia—Cisplatin—urinary bladder cancer	0.000238	0.00198	CcSEcCtD
Vidarabine—Convulsion—Etoposide—urinary bladder cancer	0.000238	0.00197	CcSEcCtD
Vidarabine—Hypertension—Etoposide—urinary bladder cancer	0.000237	0.00197	CcSEcCtD
Vidarabine—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000236	0.00196	CcSEcCtD
Vidarabine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000235	0.00195	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000235	0.00195	CcSEcCtD
Vidarabine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000234	0.00194	CcSEcCtD
Vidarabine—Chest pain—Etoposide—urinary bladder cancer	0.000234	0.00194	CcSEcCtD
Vidarabine—Somnolence—Gemcitabine—urinary bladder cancer	0.000233	0.00193	CcSEcCtD
Vidarabine—Affect lability—Doxorubicin—urinary bladder cancer	0.000233	0.00193	CcSEcCtD
Vidarabine—ADA—Metabolism—UGT2B7—urinary bladder cancer	0.000232	0.00281	CbGpPWpGaD
Vidarabine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000231	0.00192	CcSEcCtD
Vidarabine—Discomfort—Etoposide—urinary bladder cancer	0.000231	0.00192	CcSEcCtD
Vidarabine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00023	0.00191	CcSEcCtD
Vidarabine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00023	0.00191	CcSEcCtD
Vidarabine—Somnolence—Fluorouracil—urinary bladder cancer	0.000229	0.0019	CcSEcCtD
Vidarabine—Hypotension—Cisplatin—urinary bladder cancer	0.000228	0.0019	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—HRAS—urinary bladder cancer	0.000228	0.00276	CbGpPWpGaD
Vidarabine—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000226	0.00188	CcSEcCtD
Vidarabine—ADK—Metabolism—TYMP—urinary bladder cancer	0.000226	0.00273	CbGpPWpGaD
Vidarabine—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.000225	0.00186	CcSEcCtD
Vidarabine—Pain—Gemcitabine—urinary bladder cancer	0.000224	0.00186	CcSEcCtD
Vidarabine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000224	0.00186	CcSEcCtD
Vidarabine—Mood swings—Doxorubicin—urinary bladder cancer	0.000224	0.00186	CcSEcCtD
Vidarabine—Asthenia—Thiotepa—urinary bladder cancer	0.000224	0.00186	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000223	0.00185	CcSEcCtD
Vidarabine—Pain—Fluorouracil—urinary bladder cancer	0.00022	0.00183	CcSEcCtD
Vidarabine—Paraesthesia—Cisplatin—urinary bladder cancer	0.000219	0.00182	CcSEcCtD
Vidarabine—Tachycardia—Etoposide—urinary bladder cancer	0.000218	0.00181	CcSEcCtD
Vidarabine—Dyspnoea—Cisplatin—urinary bladder cancer	0.000218	0.00181	CcSEcCtD
Vidarabine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000216	0.0018	CcSEcCtD
Vidarabine—Drowsiness—Methotrexate—urinary bladder cancer	0.00021	0.00175	CcSEcCtD
Vidarabine—Hypotension—Etoposide—urinary bladder cancer	0.000209	0.00174	CcSEcCtD
Vidarabine—Pain—Cisplatin—urinary bladder cancer	0.000209	0.00173	CcSEcCtD
Vidarabine—ADA—Metabolism—CYP4B1—urinary bladder cancer	0.000209	0.00253	CbGpPWpGaD
Vidarabine—Dizziness—Thiotepa—urinary bladder cancer	0.000206	0.00171	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—TYMS—urinary bladder cancer	0.000206	0.00249	CbGpPWpGaD
Vidarabine—Urticaria—Fluorouracil—urinary bladder cancer	0.000205	0.0017	CcSEcCtD
Vidarabine—ADK—Metabolism—NAT2—urinary bladder cancer	0.000204	0.00247	CbGpPWpGaD
Vidarabine—Pollakiuria—Epirubicin—urinary bladder cancer	0.000204	0.00169	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—NCOR1—urinary bladder cancer	0.000203	0.00246	CbGpPWpGaD
Vidarabine—Sweating—Methotrexate—urinary bladder cancer	0.000202	0.00167	CcSEcCtD
Vidarabine—Paraesthesia—Etoposide—urinary bladder cancer	0.000201	0.00167	CcSEcCtD
Vidarabine—Dyspnoea—Etoposide—urinary bladder cancer	0.0002	0.00166	CcSEcCtD
Vidarabine—Somnolence—Etoposide—urinary bladder cancer	0.000199	0.00165	CcSEcCtD
Vidarabine—Vomiting—Thiotepa—urinary bladder cancer	0.000198	0.00164	CcSEcCtD
Vidarabine—ADA—Metabolism—SLC19A1—urinary bladder cancer	0.000197	0.00239	CbGpPWpGaD
Vidarabine—Drowsiness—Epirubicin—urinary bladder cancer	0.000197	0.00163	CcSEcCtD
Vidarabine—Rash—Thiotepa—urinary bladder cancer	0.000197	0.00163	CcSEcCtD
Vidarabine—Dermatitis—Thiotepa—urinary bladder cancer	0.000196	0.00163	CcSEcCtD
Vidarabine—Headache—Thiotepa—urinary bladder cancer	0.000195	0.00162	CcSEcCtD
Vidarabine—ADA—Metabolism—PRSS3—urinary bladder cancer	0.000192	0.00233	CbGpPWpGaD
Vidarabine—Pain—Etoposide—urinary bladder cancer	0.000191	0.00159	CcSEcCtD
Vidarabine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00019	0.00158	CcSEcCtD
Vidarabine—Sweating—Epirubicin—urinary bladder cancer	0.000189	0.00157	CcSEcCtD
Vidarabine—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000189	0.00157	CcSEcCtD
Vidarabine—Asthenia—Gemcitabine—urinary bladder cancer	0.000188	0.00156	CcSEcCtD
Vidarabine—Nausea—Thiotepa—urinary bladder cancer	0.000185	0.00154	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—FAS—urinary bladder cancer	0.000182	0.00221	CbGpPWpGaD
Vidarabine—Drowsiness—Doxorubicin—urinary bladder cancer	0.000182	0.00151	CcSEcCtD
Vidarabine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00018	0.00149	CcSEcCtD
Vidarabine—Bradycardia—Epirubicin—urinary bladder cancer	0.00018	0.00149	CcSEcCtD
Vidarabine—Urticaria—Etoposide—urinary bladder cancer	0.000178	0.00148	CcSEcCtD
Vidarabine—ADK—Metabolism—RRM2—urinary bladder cancer	0.000176	0.00213	CbGpPWpGaD
Vidarabine—Tinnitus—Methotrexate—urinary bladder cancer	0.000176	0.00146	CcSEcCtD
Vidarabine—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000176	0.00146	CcSEcCtD
Vidarabine—Asthenia—Cisplatin—urinary bladder cancer	0.000175	0.00146	CcSEcCtD
Vidarabine—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000175	0.00145	CcSEcCtD
Vidarabine—Sweating—Doxorubicin—urinary bladder cancer	0.000175	0.00145	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—PTEN—urinary bladder cancer	0.000174	0.00211	CbGpPWpGaD
Vidarabine—Dizziness—Fluorouracil—urinary bladder cancer	0.00017	0.00141	CcSEcCtD
Vidarabine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.00017	0.00141	CcSEcCtD
Vidarabine—Vomiting—Gemcitabine—urinary bladder cancer	0.000167	0.00138	CcSEcCtD
Vidarabine—Bradycardia—Doxorubicin—urinary bladder cancer	0.000166	0.00138	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—EP300—urinary bladder cancer	0.000166	0.00201	CbGpPWpGaD
Vidarabine—Rash—Gemcitabine—urinary bladder cancer	0.000165	0.00137	CcSEcCtD
Vidarabine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000165	0.00137	CcSEcCtD
Vidarabine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000165	0.00137	CcSEcCtD
Vidarabine—Tinnitus—Epirubicin—urinary bladder cancer	0.000165	0.00137	CcSEcCtD
Vidarabine—Headache—Gemcitabine—urinary bladder cancer	0.000164	0.00136	CcSEcCtD
Vidarabine—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000164	0.00136	CcSEcCtD
Vidarabine—Flushing—Epirubicin—urinary bladder cancer	0.000164	0.00136	CcSEcCtD
Vidarabine—Vomiting—Fluorouracil—urinary bladder cancer	0.000164	0.00136	CcSEcCtD
Vidarabine—ADK—Metabolism—ENO2—urinary bladder cancer	0.000163	0.00198	CbGpPWpGaD
Vidarabine—ADK—Metabolism—HPGDS—urinary bladder cancer	0.000163	0.00198	CbGpPWpGaD
Vidarabine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000163	0.00135	CcSEcCtD
Vidarabine—Rash—Fluorouracil—urinary bladder cancer	0.000163	0.00135	CcSEcCtD
Vidarabine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000162	0.00135	CcSEcCtD
Vidarabine—Headache—Fluorouracil—urinary bladder cancer	0.000161	0.00134	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—FGFR3—urinary bladder cancer	0.000161	0.00195	CbGpPWpGaD
Vidarabine—Dysgeusia—Methotrexate—urinary bladder cancer	0.000161	0.00134	CcSEcCtD
Vidarabine—Asthenia—Etoposide—urinary bladder cancer	0.000161	0.00133	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—CDK4—urinary bladder cancer	0.00016	0.00194	CbGpPWpGaD
Vidarabine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000159	0.00132	CcSEcCtD
Vidarabine—Back pain—Methotrexate—urinary bladder cancer	0.000159	0.00132	CcSEcCtD
Vidarabine—ADK—Metabolism—GSTT1—urinary bladder cancer	0.000158	0.00192	CbGpPWpGaD
Vidarabine—Arrhythmia—Epirubicin—urinary bladder cancer	0.000158	0.00131	CcSEcCtD
Vidarabine—Nausea—Gemcitabine—urinary bladder cancer	0.000156	0.00129	CcSEcCtD
Vidarabine—Vomiting—Cisplatin—urinary bladder cancer	0.000155	0.00129	CcSEcCtD
Vidarabine—Vision blurred—Methotrexate—urinary bladder cancer	0.000155	0.00129	CcSEcCtD
Vidarabine—Rash—Cisplatin—urinary bladder cancer	0.000154	0.00128	CcSEcCtD
Vidarabine—Dermatitis—Cisplatin—urinary bladder cancer	0.000154	0.00128	CcSEcCtD
Vidarabine—ADA—Metabolism—TYMP—urinary bladder cancer	0.000153	0.00186	CbGpPWpGaD
Vidarabine—Nausea—Fluorouracil—urinary bladder cancer	0.000153	0.00127	CcSEcCtD
Vidarabine—Tinnitus—Doxorubicin—urinary bladder cancer	0.000152	0.00126	CcSEcCtD
Vidarabine—Flushing—Doxorubicin—urinary bladder cancer	0.000152	0.00126	CcSEcCtD
Vidarabine—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000152	0.00126	CcSEcCtD
Vidarabine—Tension—Epirubicin—urinary bladder cancer	0.000151	0.00125	CcSEcCtD
Vidarabine—Dysgeusia—Epirubicin—urinary bladder cancer	0.000151	0.00125	CcSEcCtD
Vidarabine—Nervousness—Epirubicin—urinary bladder cancer	0.000149	0.00124	CcSEcCtD
Vidarabine—Back pain—Epirubicin—urinary bladder cancer	0.000149	0.00123	CcSEcCtD
Vidarabine—Dizziness—Etoposide—urinary bladder cancer	0.000148	0.00123	CcSEcCtD
Vidarabine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000147	0.00122	CcSEcCtD
Vidarabine—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000146	0.00121	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—PPARG—urinary bladder cancer	0.000146	0.00176	CbGpPWpGaD
Vidarabine—Nausea—Cisplatin—urinary bladder cancer	0.000145	0.0012	CcSEcCtD
Vidarabine—Vision blurred—Epirubicin—urinary bladder cancer	0.000145	0.0012	CcSEcCtD
Vidarabine—Cough—Methotrexate—urinary bladder cancer	0.000143	0.00119	CcSEcCtD
Vidarabine—Convulsion—Methotrexate—urinary bladder cancer	0.000142	0.00118	CcSEcCtD
Vidarabine—Vomiting—Etoposide—urinary bladder cancer	0.000142	0.00118	CcSEcCtD
Vidarabine—Agitation—Epirubicin—urinary bladder cancer	0.000141	0.00117	CcSEcCtD
Vidarabine—Rash—Etoposide—urinary bladder cancer	0.000141	0.00117	CcSEcCtD
Vidarabine—Dermatitis—Etoposide—urinary bladder cancer	0.000141	0.00117	CcSEcCtD
Vidarabine—Headache—Etoposide—urinary bladder cancer	0.00014	0.00116	CcSEcCtD
Vidarabine—Chest pain—Methotrexate—urinary bladder cancer	0.00014	0.00116	CcSEcCtD
Vidarabine—Tension—Doxorubicin—urinary bladder cancer	0.00014	0.00116	CcSEcCtD
Vidarabine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000139	0.00116	CcSEcCtD
Vidarabine—ADA—Metabolism—NAT2—urinary bladder cancer	0.000139	0.00168	CbGpPWpGaD
Vidarabine—Discomfort—Methotrexate—urinary bladder cancer	0.000138	0.00115	CcSEcCtD
Vidarabine—Nervousness—Doxorubicin—urinary bladder cancer	0.000138	0.00115	CcSEcCtD
Vidarabine—Syncope—Epirubicin—urinary bladder cancer	0.000138	0.00114	CcSEcCtD
Vidarabine—Back pain—Doxorubicin—urinary bladder cancer	0.000138	0.00114	CcSEcCtD
Vidarabine—Palpitations—Epirubicin—urinary bladder cancer	0.000136	0.00113	CcSEcCtD
Vidarabine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000135	0.00112	CcSEcCtD
Vidarabine—Cough—Epirubicin—urinary bladder cancer	0.000134	0.00111	CcSEcCtD
Vidarabine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000134	0.00111	CcSEcCtD
Vidarabine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000134	0.00111	CcSEcCtD
Vidarabine—Convulsion—Epirubicin—urinary bladder cancer	0.000133	0.00111	CcSEcCtD
Vidarabine—Nausea—Etoposide—urinary bladder cancer	0.000133	0.0011	CcSEcCtD
Vidarabine—Hypertension—Epirubicin—urinary bladder cancer	0.000133	0.0011	CcSEcCtD
Vidarabine—ADK—Metabolism—NQO1—urinary bladder cancer	0.000132	0.00159	CbGpPWpGaD
Vidarabine—Chest pain—Epirubicin—urinary bladder cancer	0.000131	0.00109	CcSEcCtD
Vidarabine—Agitation—Doxorubicin—urinary bladder cancer	0.000131	0.00109	CcSEcCtD
Vidarabine—Anxiety—Epirubicin—urinary bladder cancer	0.00013	0.00108	CcSEcCtD
Vidarabine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.00013	0.00108	CcSEcCtD
Vidarabine—Discomfort—Epirubicin—urinary bladder cancer	0.000129	0.00107	CcSEcCtD
Vidarabine—Dry mouth—Epirubicin—urinary bladder cancer	0.000128	0.00106	CcSEcCtD
Vidarabine—Syncope—Doxorubicin—urinary bladder cancer	0.000128	0.00106	CcSEcCtD
Vidarabine—Palpitations—Doxorubicin—urinary bladder cancer	0.000126	0.00104	CcSEcCtD
Vidarabine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000125	0.00104	CcSEcCtD
Vidarabine—Hypotension—Methotrexate—urinary bladder cancer	0.000125	0.00104	CcSEcCtD
Vidarabine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000125	0.00104	CcSEcCtD
Vidarabine—Cough—Doxorubicin—urinary bladder cancer	0.000124	0.00103	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—RHOA—urinary bladder cancer	0.000124	0.0015	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—FGFR3—urinary bladder cancer	0.000124	0.0015	CbGpPWpGaD
Vidarabine—Shock—Epirubicin—urinary bladder cancer	0.000123	0.00102	CcSEcCtD
Vidarabine—Convulsion—Doxorubicin—urinary bladder cancer	0.000123	0.00102	CcSEcCtD
Vidarabine—Hypertension—Doxorubicin—urinary bladder cancer	0.000123	0.00102	CcSEcCtD
Vidarabine—Tachycardia—Epirubicin—urinary bladder cancer	0.000122	0.00102	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000122	0.00101	CcSEcCtD
Vidarabine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000121	0.00101	CcSEcCtD
Vidarabine—Chest pain—Doxorubicin—urinary bladder cancer	0.000121	0.00101	CcSEcCtD
Vidarabine—Anxiety—Doxorubicin—urinary bladder cancer	0.000121	0.001	CcSEcCtD
Vidarabine—Paraesthesia—Methotrexate—urinary bladder cancer	0.00012	0.000999	CcSEcCtD
Vidarabine—ADA—Metabolism—RRM2—urinary bladder cancer	0.00012	0.00145	CbGpPWpGaD
Vidarabine—Discomfort—Doxorubicin—urinary bladder cancer	0.00012	0.000993	CcSEcCtD
Vidarabine—Dyspnoea—Methotrexate—urinary bladder cancer	0.00012	0.000992	CcSEcCtD
Vidarabine—Somnolence—Methotrexate—urinary bladder cancer	0.000119	0.000989	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—TP53—urinary bladder cancer	0.000119	0.00144	CbGpPWpGaD
Vidarabine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000118	0.000983	CcSEcCtD
Vidarabine—Hypotension—Epirubicin—urinary bladder cancer	0.000117	0.000973	CcSEcCtD
Vidarabine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000116	0.000964	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—ERBB2—urinary bladder cancer	0.000115	0.00139	CbGpPWpGaD
Vidarabine—Pain—Methotrexate—urinary bladder cancer	0.000115	0.000952	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000114	0.000949	CcSEcCtD
Vidarabine—Shock—Doxorubicin—urinary bladder cancer	0.000114	0.000948	CcSEcCtD
Vidarabine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000113	0.000941	CcSEcCtD
Vidarabine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000113	0.000935	CcSEcCtD
Vidarabine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000112	0.000932	CcSEcCtD
Vidarabine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000112	0.000929	CcSEcCtD
Vidarabine—Somnolence—Epirubicin—urinary bladder cancer	0.000112	0.000926	CcSEcCtD
Vidarabine—ADA—Metabolism—ENO2—urinary bladder cancer	0.000111	0.00134	CbGpPWpGaD
Vidarabine—ADA—Metabolism—HPGDS—urinary bladder cancer	0.000111	0.00134	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GSTP1—urinary bladder cancer	0.00011	0.00133	CbGpPWpGaD
Vidarabine—Hypotension—Doxorubicin—urinary bladder cancer	0.000109	0.000901	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—IGF1—urinary bladder cancer	0.000108	0.00131	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTT1—urinary bladder cancer	0.000108	0.0013	CbGpPWpGaD
Vidarabine—Pain—Epirubicin—urinary bladder cancer	0.000107	0.000891	CcSEcCtD
Vidarabine—Urticaria—Methotrexate—urinary bladder cancer	0.000107	0.000884	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000106	0.000878	CcSEcCtD
Vidarabine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000104	0.000865	CcSEcCtD
Vidarabine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000104	0.000859	CcSEcCtD
Vidarabine—Somnolence—Doxorubicin—urinary bladder cancer	0.000103	0.000857	CcSEcCtD
Vidarabine—ADK—Metabolism—TYMS—urinary bladder cancer	0.000102	0.00124	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GSTM1—urinary bladder cancer	0.000101	0.00122	CbGpPWpGaD
Vidarabine—ADK—Metabolism—NCOR1—urinary bladder cancer	0.000101	0.00122	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—PTEN—urinary bladder cancer	9.99e-05	0.00121	CbGpPWpGaD
Vidarabine—Urticaria—Epirubicin—urinary bladder cancer	9.97e-05	0.000827	CcSEcCtD
Vidarabine—Pain—Doxorubicin—urinary bladder cancer	9.93e-05	0.000824	CcSEcCtD
Vidarabine—Hypersensitivity—Methotrexate—urinary bladder cancer	9.88e-05	0.00082	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1A—urinary bladder cancer	9.82e-05	0.00119	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PTEN—urinary bladder cancer	9.79e-05	0.00119	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GPX1—urinary bladder cancer	9.65e-05	0.00117	CbGpPWpGaD
Vidarabine—Asthenia—Methotrexate—urinary bladder cancer	9.62e-05	0.000799	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—RHOA—urinary bladder cancer	9.54e-05	0.00116	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—EP300—urinary bladder cancer	9.53e-05	0.00115	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ERCC2—urinary bladder cancer	9.48e-05	0.00115	CbGpPWpGaD
Vidarabine—Hypersensitivity—Epirubicin—urinary bladder cancer	9.25e-05	0.000767	CcSEcCtD
Vidarabine—Urticaria—Doxorubicin—urinary bladder cancer	9.22e-05	0.000766	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—SRC—urinary bladder cancer	9.08e-05	0.0011	CbGpPWpGaD
Vidarabine—Asthenia—Epirubicin—urinary bladder cancer	9e-05	0.000747	CcSEcCtD
Vidarabine—ADA—Metabolism—NQO1—urinary bladder cancer	8.94e-05	0.00108	CbGpPWpGaD
Vidarabine—ADK—Metabolism—MTHFR—urinary bladder cancer	8.91e-05	0.00108	CbGpPWpGaD
Vidarabine—Dizziness—Methotrexate—urinary bladder cancer	8.87e-05	0.000736	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—ERBB2—urinary bladder cancer	8.83e-05	0.00107	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HDAC4—urinary bladder cancer	8.79e-05	0.00107	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—CXCL8—urinary bladder cancer	8.72e-05	0.00106	CbGpPWpGaD
Vidarabine—Hypersensitivity—Doxorubicin—urinary bladder cancer	8.55e-05	0.00071	CcSEcCtD
Vidarabine—Vomiting—Methotrexate—urinary bladder cancer	8.53e-05	0.000708	CcSEcCtD
Vidarabine—Rash—Methotrexate—urinary bladder cancer	8.46e-05	0.000702	CcSEcCtD
Vidarabine—Dermatitis—Methotrexate—urinary bladder cancer	8.45e-05	0.000701	CcSEcCtD
Vidarabine—Headache—Methotrexate—urinary bladder cancer	8.4e-05	0.000697	CcSEcCtD
Vidarabine—Asthenia—Doxorubicin—urinary bladder cancer	8.33e-05	0.000691	CcSEcCtD
Vidarabine—Dizziness—Epirubicin—urinary bladder cancer	8.3e-05	0.000689	CcSEcCtD
Vidarabine—Vomiting—Epirubicin—urinary bladder cancer	7.98e-05	0.000662	CcSEcCtD
Vidarabine—Nausea—Methotrexate—urinary bladder cancer	7.97e-05	0.000661	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—urinary bladder cancer	7.96e-05	0.000965	CbGpPWpGaD
Vidarabine—Rash—Epirubicin—urinary bladder cancer	7.91e-05	0.000657	CcSEcCtD
Vidarabine—Dermatitis—Epirubicin—urinary bladder cancer	7.91e-05	0.000656	CcSEcCtD
Vidarabine—Headache—Epirubicin—urinary bladder cancer	7.86e-05	0.000653	CcSEcCtD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	7.79e-05	0.000944	CbGpPWpGaD
Vidarabine—Dizziness—Doxorubicin—urinary bladder cancer	7.68e-05	0.000637	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—CDKN1A—urinary bladder cancer	7.55e-05	0.000915	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PTEN—urinary bladder cancer	7.53e-05	0.000913	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—urinary bladder cancer	7.52e-05	0.000911	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTP1—urinary bladder cancer	7.46e-05	0.000903	CbGpPWpGaD
Vidarabine—Nausea—Epirubicin—urinary bladder cancer	7.45e-05	0.000619	CcSEcCtD
Vidarabine—Vomiting—Doxorubicin—urinary bladder cancer	7.38e-05	0.000613	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—GLI1—urinary bladder cancer	7.37e-05	0.000893	CbGpPWpGaD
Vidarabine—Rash—Doxorubicin—urinary bladder cancer	7.32e-05	0.000608	CcSEcCtD
Vidarabine—Dermatitis—Doxorubicin—urinary bladder cancer	7.31e-05	0.000607	CcSEcCtD
Vidarabine—Headache—Doxorubicin—urinary bladder cancer	7.27e-05	0.000604	CcSEcCtD
Vidarabine—ADK—Metabolism—PPARG—urinary bladder cancer	7.22e-05	0.000875	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—SRC—urinary bladder cancer	6.99e-05	0.000846	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CREBBP—urinary bladder cancer	6.94e-05	0.000841	CbGpPWpGaD
Vidarabine—ADA—Metabolism—TYMS—urinary bladder cancer	6.93e-05	0.00084	CbGpPWpGaD
Vidarabine—Nausea—Doxorubicin—urinary bladder cancer	6.9e-05	0.000572	CcSEcCtD
Vidarabine—ADA—Metabolism—GSTM1—urinary bladder cancer	6.85e-05	0.00083	CbGpPWpGaD
Vidarabine—ADA—Metabolism—NCOR1—urinary bladder cancer	6.85e-05	0.00083	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—TP53—urinary bladder cancer	6.82e-05	0.000826	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GPX1—urinary bladder cancer	6.56e-05	0.000795	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ERCC2—urinary bladder cancer	6.44e-05	0.000781	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—urinary bladder cancer	6.39e-05	0.000775	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—EGFR—urinary bladder cancer	6.12e-05	0.000742	CbGpPWpGaD
Vidarabine—ADA—Metabolism—MTHFR—urinary bladder cancer	6.06e-05	0.000734	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CXCL8—urinary bladder cancer	5.94e-05	0.000719	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—KRAS—urinary bladder cancer	5.78e-05	0.000701	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PTGS2—urinary bladder cancer	5.68e-05	0.000689	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RBX1—urinary bladder cancer	5.05e-05	0.000612	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PTEN—urinary bladder cancer	4.96e-05	0.000601	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—HRAS—urinary bladder cancer	4.92e-05	0.000596	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PPARG—urinary bladder cancer	4.91e-05	0.000595	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TSC1—urinary bladder cancer	4.75e-05	0.000575	CbGpPWpGaD
Vidarabine—ADK—Metabolism—EP300—urinary bladder cancer	4.73e-05	0.000573	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CREBBP—urinary bladder cancer	4.72e-05	0.000572	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—JAG1—urinary bladder cancer	4.52e-05	0.000548	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PTGS2—urinary bladder cancer	3.86e-05	0.000468	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—RHOA—urinary bladder cancer	3.82e-05	0.000463	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—S100B—urinary bladder cancer	3.66e-05	0.000443	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—RHOA—urinary bladder cancer	3.47e-05	0.00042	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PTEN—urinary bladder cancer	3.37e-05	0.000408	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.35e-05	0.000406	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NCOR1—urinary bladder cancer	3.29e-05	0.000399	CbGpPWpGaD
Vidarabine—ADA—Metabolism—EP300—urinary bladder cancer	3.21e-05	0.000389	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—IL2—urinary bladder cancer	3.21e-05	0.000388	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CXCL8—urinary bladder cancer	3.05e-05	0.000369	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL2—urinary bladder cancer	2.91e-05	0.000353	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TERT—urinary bladder cancer	2.9e-05	0.000351	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FGFR3—urinary bladder cancer	2.66e-05	0.000322	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ESR1—urinary bladder cancer	2.59e-05	0.000313	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CREBBP—urinary bladder cancer	2.27e-05	0.000275	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IGF1—urinary bladder cancer	2.24e-05	0.000271	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—EGFR—urinary bladder cancer	2.23e-05	0.00027	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—KRAS—urinary bladder cancer	2.1e-05	0.000255	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RHOA—urinary bladder cancer	2.05e-05	0.000248	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ERBB2—urinary bladder cancer	1.9e-05	0.00023	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCL8—urinary bladder cancer	1.8e-05	0.000218	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—HRAS—urinary bladder cancer	1.79e-05	0.000217	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL2—urinary bladder cancer	1.72e-05	0.000208	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCND1—urinary bladder cancer	1.68e-05	0.000203	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MMP9—urinary bladder cancer	1.63e-05	0.000197	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.62e-05	0.000196	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTEN—urinary bladder cancer	1.62e-05	0.000196	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EP300—urinary bladder cancer	1.54e-05	0.000187	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SRC—urinary bladder cancer	1.5e-05	0.000182	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MYC—urinary bladder cancer	1.34e-05	0.000163	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EGFR—urinary bladder cancer	1.32e-05	0.000159	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KRAS—urinary bladder cancer	1.24e-05	0.000151	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TP53—urinary bladder cancer	1.1e-05	0.000134	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HRAS—urinary bladder cancer	1.06e-05	0.000128	CbGpPWpGaD
